Categoria: Abstract

Home / Abstract
Articolo

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Authors: Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Stephens, Shahneen Kaur Sandhu, Ragini Reiney...

Articolo

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma Authors: Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani,...

Articolo

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma Authors: Rodabe Navroze Amaria, Michael A. Postow, Michael T. Tetzlaff, Merrick I. Ross, Isabella Claudia Glitza, Jennifer Leigh McQuade, Michael K.K. Wong, Jeffrey E. Gershenwald, Ryan Goepfert, Emily Zhi-Yun Keung, Sarah B. Fisher, Denai R. Milton,...

Articolo

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047) Authors: Evan J. Lipson, Hussein Abdul-Hassan Tawbi, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski de Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Shivani Srivastava,...

Articolo

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004 Authors: Ana Maria Arance, Luis de la Cruz-Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Marquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Alan...

Articolo

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy James Larkin, Amod Sarnaik, Jason Alan Chesney, Nikhil I. Khushalani, John M. Kirkwood, Jeffrey S. Weber, Karl D. Lewis, Theresa Michelle Medina, Harriet M. Kluger, Sajeve Samuel Thomas, Evidio Domingo-Musibay, Judit Olah, Eric...

Articolo

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma Authors: Reinhard Dummer, Keith Flaherty, Caroline Robert, Ana Maria Arance, Jan Willem de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk...

Articolo

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA Authors: Erika Richtig, Ralf Gutzmer, Carmen Loquai, Jochen Utikal, Christoph Hoeller, Rudolf Stadler, Andrea Forschner, Jessica Cecile Hassel, Daniela Goeppner, Michael Fluck, Sebastian Haferkamp, Martin Kaatz, Manfred Welslau, Reinhard Dummer, Roger...

Articolo

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D. Lao, Charles Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O. Butler, Andrew Graham Hill, Ivan Marquez-Rodas, John B. A. G. Haanen, Tuba Bas, Wim...

Articolo

Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.

Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma. Authors: Max Jameson-Lee, Patrick Alexander Ott, Jason J. Luke, Michael A. Postow, Andrew Stewart Poklepovic; UPMC Hillman Cancer Center, Pittsburgh, PA; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY;...